High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
25 05 2020
Historique:
received: 10 03 2020
accepted: 04 05 2020
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 22 6 2021
Statut: epublish

Résumé

Symptomatic spinal stenosis (SSS) is a well-known medical complication in achondroplasia. The reported prevalence of SSS is 10 to 30%, an estimate based on small studies or selected populations. No population-based studies exist currently. Furthermore, the relationship between SSS and physical functioning has not been investigated in detail. The aims of this study were to describe the prevalence of SSS in Norwegian adults with achondroplasia, and to explore the impact of SSS on physical functioning. This was a population-based study on Norwegian community-dwelling adults with genetically confirmed achondroplasia. Prevalence of SSS was defined by clinical symptoms, and confirmed by imaging or surgical reports. Physical functioning was assessed by walking capacity (6-min walk test), hand strength (Grippit), and activities of daily living (the Health Assessment Questionnaire, HAQ). Pain was assessed by pain site locations and intensity (Numeric Rating Scale, NRS). In total, 50 participants were included (27 males, 23 females). Median age was 41 years (range 16 to 87 years), 34 (68%) had SSS. The estimated median age at first symptom onset was 33 years (95% confidence interval (CI) 29 to 43 years), range 10 to 67 years. The majority had multiple spinal levels affected. The walking distance was 110 m shorter in the SSS group (95% CI - 172 to - 40 m) as compared with the non-SSS group (p < 0.01). There was no considerable difference in hand strength between the two groups. Mean HAQ scores (0-3) for walking and hygiene were significantly higher in the SSS group, reflecting more activity limitations. Mean differences were 0.9 (95% CI 0.3 to 1.4, p < 0.01) and 0.6 (95% CI 0.2 to 1.0, p < 0.01). Pain intensity (NRS 0-10) was also significantly higher in the SSS group with a mean difference of 3.2 (95% CI 0.6 to 5.6, p = 0.02). SSS was highly prevalent in Norwegian adults with achondroplasia, with symptom onset at young age, and multiple spinal levels affected. The presence of SSS was associated with reduced walking distance, activity limitations, and more pain. The findings underline the importance of thorough assessment and monitoring of SSS in achondroplasia, including a formal assessment of physical functioning.

Sections du résumé

BACKGROUND
Symptomatic spinal stenosis (SSS) is a well-known medical complication in achondroplasia. The reported prevalence of SSS is 10 to 30%, an estimate based on small studies or selected populations. No population-based studies exist currently. Furthermore, the relationship between SSS and physical functioning has not been investigated in detail. The aims of this study were to describe the prevalence of SSS in Norwegian adults with achondroplasia, and to explore the impact of SSS on physical functioning.
METHODS
This was a population-based study on Norwegian community-dwelling adults with genetically confirmed achondroplasia. Prevalence of SSS was defined by clinical symptoms, and confirmed by imaging or surgical reports. Physical functioning was assessed by walking capacity (6-min walk test), hand strength (Grippit), and activities of daily living (the Health Assessment Questionnaire, HAQ). Pain was assessed by pain site locations and intensity (Numeric Rating Scale, NRS).
RESULTS
In total, 50 participants were included (27 males, 23 females). Median age was 41 years (range 16 to 87 years), 34 (68%) had SSS. The estimated median age at first symptom onset was 33 years (95% confidence interval (CI) 29 to 43 years), range 10 to 67 years. The majority had multiple spinal levels affected. The walking distance was 110 m shorter in the SSS group (95% CI - 172 to - 40 m) as compared with the non-SSS group (p < 0.01). There was no considerable difference in hand strength between the two groups. Mean HAQ scores (0-3) for walking and hygiene were significantly higher in the SSS group, reflecting more activity limitations. Mean differences were 0.9 (95% CI 0.3 to 1.4, p < 0.01) and 0.6 (95% CI 0.2 to 1.0, p < 0.01). Pain intensity (NRS 0-10) was also significantly higher in the SSS group with a mean difference of 3.2 (95% CI 0.6 to 5.6, p = 0.02).
CONCLUSIONS
SSS was highly prevalent in Norwegian adults with achondroplasia, with symptom onset at young age, and multiple spinal levels affected. The presence of SSS was associated with reduced walking distance, activity limitations, and more pain. The findings underline the importance of thorough assessment and monitoring of SSS in achondroplasia, including a formal assessment of physical functioning.

Identifiants

pubmed: 32450891
doi: 10.1186/s13023-020-01397-6
pii: 10.1186/s13023-020-01397-6
pmc: PMC7249360
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

123

Commentaires et corrections

Type : ErratumIn

Références

J Neurosurg Spine. 2010 Sep;13(3):335-40
pubmed: 20809726
Calcif Tissue Int. 2019 Apr;104(4):364-372
pubmed: 30706088
Qual Life Res. 2019 Jun;28(6):1457-1464
pubmed: 30637564
J Am Acad Orthop Surg. 2016 Dec;24(12):843-852
pubmed: 27849674
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S350-70
pubmed: 22588756
Am J Med Genet A. 2007 Nov 1;143A(21):2502-11
pubmed: 17879967
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Dev Dyn. 2017 Apr;246(4):291-309
pubmed: 27987249
Am J Med Genet A. 2019 Sep;179(9):1791-1798
pubmed: 31294928
N Engl J Med. 2008 Feb 21;358(8):818-25
pubmed: 18287604
J Pediatr Orthop. 1997 Nov-Dec;17(6):726-33
pubmed: 9591973
Qual Life Res. 2017 May;26(5):1337-1348
pubmed: 27866314
Scand J Rheumatol. 1993;22(1):14-9
pubmed: 8434241
Br J Anaesth. 2008 Jul;101(1):17-24
pubmed: 18487245
J Bone Joint Surg Br. 2006 Sep;88(9):1192-6
pubmed: 16943471
Endocr Rev. 2000 Feb;21(1):23-39
pubmed: 10696568
Am J Med Genet. 1987 Oct;28(2):433-44
pubmed: 3425618
Tidsskr Nor Laegeforen. 2008 Sep 25;128(18):2082-4
pubmed: 18846126
J Appl Physiol (1985). 2018 Mar 1;124(3):696-703
pubmed: 29146686
JAMA. 2010 Dec 15;304(23):2628-36
pubmed: 21156951
N Engl J Med. 2016 Apr 14;374(15):1413-23
pubmed: 27074066
Spine (Phila Pa 1976). 2011 May 15;36(11):886-92
pubmed: 20739914
Clin Genet. 2013 Sep;84(3):237-43
pubmed: 23106480
Spine Deform. 2016 Mar;4(2):145-148
pubmed: 27927547
J Pediatr Orthop. 2007 Mar;27(2):119-22
pubmed: 17314632
Orphanet J Rare Dis. 2019 Jan 3;14(1):1
pubmed: 30606190
BMC Musculoskelet Disord. 2011 Jul 28;12:175
pubmed: 21798008
Arch Dis Child. 2012 Feb;97(2):129-34
pubmed: 21460402
J Bone Joint Surg Br. 2007 Jan;89(1):57-61
pubmed: 17259417
Acta Paediatr. 2002;91(6):617-25
pubmed: 12162590
Spine J. 2013 Jul;13(7):734-43
pubmed: 23830297
J Rheumatol. 2003 Jan;30(1):167-78
pubmed: 12508408
Sci Rep. 2020 Mar 13;10(1):4699
pubmed: 32170149
Spine J. 2009 Jul;9(7):545-50
pubmed: 19398386
Basic Life Sci. 1988;48:3-9
pubmed: 3071358
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S297-307
pubmed: 22588752
J Eval Clin Pract. 2017 Apr;23(2):377-381
pubmed: 27592691
Ann Intern Med. 2008 Mar 18;148(6):449-58
pubmed: 18268289
Scand J Occup Ther. 2012 May;19(3):288-96
pubmed: 21355705
J Neurosurg. 2007 May;106(5 Suppl):372-8
pubmed: 17566204
J Med Genet. 1998 Sep;35(9):705-12
pubmed: 9733026
Clin Genet. 2020 Jan;97(1):179-197
pubmed: 30916780
J Neurosurg. 2002 Apr;96(3 Suppl):292-7
pubmed: 11990837
Curr Neurol Neurosci Rep. 2019 Nov 28;19(12):105
pubmed: 31782047
Curr Osteoporos Rep. 2017 Apr;15(2):53-60
pubmed: 28224446
Orthop Clin North Am. 1975 Jan;6(1):177-96
pubmed: 1113966
Int J Surg. 2014 Dec;12(12):1495-9
pubmed: 25046131

Auteurs

Svein O Fredwall (SO)

Sunnaas Rehabilitation Hospital, TRS National Resource Centre for Rare Disorders, Nesodden, Norway. svfred@sunnaas.no.
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. svfred@sunnaas.no.

Unni Steen (U)

Sunnaas Rehabilitation Hospital, TRS National Resource Centre for Rare Disorders, Nesodden, Norway.

Olga de Vries (O)

Sunnaas Rehabilitation Hospital, TRS National Resource Centre for Rare Disorders, Nesodden, Norway.

Cecilie F Rustad (CF)

Oslo University Hospital, Department of Medical Genetics, Oslo, Norway.

Heidi Beate Eggesbø (HB)

Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo, Norway.

Harald Weedon-Fekjær (H)

Oslo Centre for Biostatistics and Epidemiology, Research Support Service, Oslo University Hospital, Oslo, Norway.

Ingeborg B Lidal (IB)

Sunnaas Rehabilitation Hospital, TRS National Resource Centre for Rare Disorders, Nesodden, Norway.

Ravi Savarirayan (R)

Murdoch Children's Research Institute and University of Melbourne, Parkville, Australia.

Grethe Månum (G)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Sunnaas Rehabilitation Hospital, Department of Research, Nesodden, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH